NuCana plc

NuCana plcverified

NCNA

Price:

$3.26

Market Cap:

$5.93M

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformati...[Read more]

Industry

Biotechnology

IPO Date

2017-09-28

Stock Exchange

NASDAQ

Ticker

NCNA

The PE Ratio as of September 2024 (TTM) for NuCana plc (NCNA) is -0.19

According to NuCana plc’s latest financial reports and current stock price. The company's current PE Ratio is -0.19. This represents a change of -61.21% compared to the average of -0.49 of the last 4 quarters.

NuCana plc (NCNA) Historical PE Ratio (quarterly & annually)

How has NCNA PE Ratio performed in the past?

The mean historical PE Ratio of NuCana plc over the last ten years is -5202.05. The current -0.19 PE Ratio has changed -99.63% with respect to the historical average. Over the past ten years (40 quarters), NCNA's PE Ratio was at its highest in in the June 2024 quarter at -0.18. The PE Ratio was at its lowest in in the December 2016 quarter at -1344.87.

Quarterly (TTM)
Annual

Average

-5202.05

Median

-7.62

Minimum

-51841.09

Maximum

-0.47

NuCana plc (NCNA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of NuCana plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 212.57%

Maximum Annual PE Ratio = -0.47

Minimum Annual Increase = -99.88%

Minimum Annual PE Ratio = -51841.09

Quarterly (TTM)
Annual
YearPE RatioChange
2023-0.47-46.14%
2022-0.88-60.58%
2021-2.24-44.89%
2020-4.06-40.66%
2019-6.84-73.96%
2018-26.26212.57%
2017-8.40-87.42%
2016-66.795.22%
2015-63.48-99.88%

NuCana plc (NCNA) Average PE Ratio

How has NCNA PE Ratio performed in the past?

The current PE Ratio of NuCana plc (NCNA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-1.20

5-year avg

-2.90

10-year avg

-5202.05

NuCana plc (NCNA) PE Ratio vs. Peers

How is NCNA’s PE Ratio compared to its peers?

NuCana plc’s PE Ratio is less than eFFECTOR Therapeutics, Inc. (0), less than Virios Therapeutics, Inc. (-0.01), greater than Zura Bio Limited (-0.99), greater than Navidea Biopharmaceuticals, Inc. (-10.69), less than ZyVersa Therapeutics, Inc. (0.03), less than Cidara Therapeutics, Inc. (-0.09), greater than Silence Therapeutics plc (-0.47), greater than Applied Therapeutics, Inc. (-16.06), greater than CytomX Therapeutics, Inc. (-7.15), less than Rani Therapeutics Holdings, Inc. (8.96), less than Vincerx Pharma, Inc. (0), greater than Tenaya Therapeutics, Inc. (-1.99), greater than Corvus Pharmaceuticals, Inc. (-0.93), greater than ALX Oncology Holdings Inc. (-1.55), greater than Mereo BioPharma Group plc (-14.81), greater than Acumen Pharmaceuticals, Inc. (-0.66), greater than Day One Biopharmaceuticals, Inc. (-18.01), greater than Inozyme Pharma, Inc. (-2.39), greater than Galera Therapeutics, Inc. (-7.45), greater than null (-4.04), less than null (-0.15),

Build a custom stock screener for NuCana plc (NCNA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NuCana plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

NuCana plc (NCNA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like NuCana plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is NuCana plc's PE Ratio?

How is the PE Ratio calculated for NuCana plc (NCNA)?

What is the highest PE Ratio for NuCana plc (NCNA)?

What is the 3-year average PE Ratio for NuCana plc (NCNA)?

What is the 5-year average PE Ratio for NuCana plc (NCNA)?

How does the current PE Ratio for NuCana plc (NCNA) compare to its historical average?